A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Ganciclovir and Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders.

Trial Profile

A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Ganciclovir and Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2011

At a glance

  • Drugs Arginine butyrate; Ganciclovir; Valganciclovir
  • Indications Epstein-Barr virus infections; Lymphoma; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2011 Planned end date changed from 1 Jan 2011 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top